Granted Patent
B2
US 12,329,758 · App. 17/057,946 · Granted Jun 17, 2025
Methods for the treatment of psoriatic arthritis
Inventors:
Pille Harrison (Juan les Pins, FR); Luc Meuleners (Mechelen, BE); Chantal Thérèse Tasset (Mechelen, BE)
Assignee:
ALFASIGMA S.P.A.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.
Claims (13)
1. A method for treating a patient diagnosed with psoriatic arthritis, comprising administering a compound according to formula I:
or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof to the patient, wherein the compound is dosed at a daily dose of 100 to 200 mg, and wherein the patient has never been exposed to anti-TNF treatment or had an inadequate response prior to anti-TNF treatment, wherein the compound is dosed for a period of at least 16 weeks.
2. The method of claim 1 , wherein the compound is dosed once (q.d.) or twice daily (b.i.d.).
3. The method of claim 1 , wherein the treatment induces a treatment effect characterized by an American College of Rheumatology (ACR)20-score of at least 70%.
4. The method of claim 1 , wherein the treatment induces a treatment effect characterized by an American College of Rheumatology (ACR50)-score of at least 40%.
5. The method of claim 1 , wherein the patient diagnosed with psoriatic arthritis displays clinical signs and symptoms of enthesitis.
6. The method of claim 1 , wherein the patient diagnosed with psoriatic arthritis has a Leeds Enthesitis Index (LEI) score of more than 0.
7. The method of claim 5 , wherein the treatment induces a treatment effect characterized by a reduction of LEI score of at least 0.8.
8. The method of claim 1 , wherein the treatment induces a treatment effect characterized by a reduction of Health Assessment Questionnaire without Disability Index (HAQ-DI) score of at least 0.35.
9. The method of claim 3 , wherein the treatment effect is seen at week 12 of the treatment.
10. The method of claim 3 , wherein the treatment effect is seen at week 16 of the treatment.
11. The method of claim 1 , wherein the patient diagnosed with psoriatic arthritis displays more than 3% body surface area (BSA) psoriasis.
12. The method of claim 1 , wherein the patient does not concomitantly receive any additional treatment for psoriatic arthritis, or, wherein the patient does not concomitantly receive any anti-TNF treatment.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 16, 2024
From: GALAPAGOS NV
To: ALFASIGMA S.P.A.
Reel/Frame 067126/0592 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 23, 2020
From: HARRISON, PILLE; MEULENERS, LUC; TASSET, CHANTAL THÉRÈSE
To: GALAPAGOS NV
Reel/Frame 054447/0108 →
Priority Claims (1)
GB 1808575
· May 24, 2018
· national
Continuity (1)
References Cited (142)
US 6500854B1
· Kitamura et al.
· 2002
[cited by applicant]
US 8088764B2
· Menet et al.
· 2012
[cited by applicant]
US 8242274B2
· Menet et al.
· 2012
[cited by applicant]
US 8563545B2
· Menet et al.
· 2013
[cited by applicant]
US 8853240B2
· Menet et al.
· 2014
[cited by applicant]
US 8999979B2
· Menet et al.
· 2015
[cited by applicant]
US 9284311B2
· van 't Klooster et al.
· 2016
[cited by applicant]
US 9309244B2
· Menet et al.
· 2016
[cited by applicant]
US 9382247B2
· Sabourault et al.
· 2016
[cited by applicant]
US 9415037B2
· Menet et al.
· 2016
[cited by applicant]
US 9707237B2
· Menet et al.
· 2017
[cited by applicant]
US 20050222171A1
· Bold et al.
· 2005
[cited by applicant]
US 20130310340A1
· Payan et al.
· 2013
[cited by applicant]
US 20170173034A1
· Di Paolo
· 2017
[cited by applicant]
US 20180263997A1
· Alonzo
· 2018
[cited by examiner]
EP 1391211A1
· 2004
[cited by applicant]
EP 2305673A1
· 2011
[cited by applicant]
EP 2445911A1
· 2012
[cited by applicant]
EP 2778159A1
· 2014
[cited by applicant]
JP 2013049632A
· 2013
[cited by applicant]
WO 2003010167A1
· 2003
[cited by applicant]
WO 2004039816A1
· 2004
[cited by applicant]
WO 2004072072A1
· 2004
[cited by applicant]
WO 2005124342A2
· 2005
[cited by applicant]
WO 2006018735A2
· 2006
[cited by applicant]
WO 2006038116A2
· 2006
[cited by applicant]
WO 2007009773A1
· 2007
[cited by applicant]
WO 2008025821A1
· 2008
[cited by applicant]
WO 2008150015A1
· 2008
[cited by applicant]
WO 2009010530A1
· 2009
[cited by applicant]
WO 2009017954A1
· 2009
[cited by applicant]
WO 2009027283A1
· 2009
[cited by applicant]
WO 2009047514A1
· 2009
[cited by applicant]
WO 2009155565A1
· 2009
[cited by applicant]
WO 2010010184A1
· 2010
[cited by applicant]
WO 2010010186A1
· 2010
[cited by applicant]
WO 2010010187A1
· 2010
[cited by applicant]
WO 2010010188A1
· 2010
[cited by applicant]
WO 2010010189A1
· 2010
[cited by applicant]
WO 2010010190A1
· 2010
[cited by applicant]
WO 2010010191A1
· 2010
[cited by applicant]
WO 2010013768A1
· 2010
[cited by applicant]
WO 2010149769A1
· 2010
[cited by applicant]
WO 2013069297A1
· 2013
[cited by applicant]
WO 2013189771A1
· 2013
[cited by applicant]
WO 2015117980A1
· 2015
[cited by applicant]
WO 2016165953A1
· 2016
[cited by applicant]
Mease et al, Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis, 2017, N. Engl. J. of Med, vol. 377, No. 16, p. 1537-1550. (Year: 2017).
[cited by examiner]
International Search Report and Written Opinion issued in PCT/EP2019/063283 dated Aug. 22, 2019, pp. 1-13.
[cited by applicant]
Mease P. et al., “Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-modifying Anti-rheumatic Drugs: Results from a …
[cited by applicant]
Mease P. et al.,“Efficacy and Safety of Filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (Equator): results from a randomised, placebo-controlled, phase 2 trial,” Lancet, 201…
[cited by applicant]
Robin-Jagerschmidt C., et al., “The JAK1 selective inhibitor Filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis,” Annals of the rheumathic diseases, 2017, vol. 76, No. 2, p…
[cited by applicant]
Argiles 1998 Curr Opin Clin Nutr Metab Care. 1: pp. 245-251.
[cited by applicant]
Bain, J, 2003, biochem J371: pp. 199-204.
[cited by applicant]
Bastin R J: “Salt selection and optimisation procedures for pharmaceutical new chemical entities”, Organic Process Research & Development, vol. 4(5), 2000, pp. 427-435.
[cited by applicant]
Berge et al. “Pharmaceutical salts”, Jan. 1977, Journal of Pharm. Sciences, vol. 66, N. 1, pp. 1-19.
[cited by applicant]
Berishaj et al., “Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer”, Breast Cancer Res., 2007, vol. 9(3), R32.
[cited by applicant]
Bundgard., “Prodrugs as a Means to Improve the Delivery of Peptide Drugs,” Adv. Drug Del Rev., vol. 8, 1992, pp. 1-38.
[cited by applicant]
Bush et al., “Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 recetor IgGl Fe fusion protein”, 2002, Arthritis Rheum., vol. 46, pp. 802-805.
[cited by applicant]
Changelian et al., “The specificity of JAK3 kinase inhibitors”, Blood, 2008, vol. 111, pp. 2155-2157.
[cited by applicant]
Chen et al., “Janus kinase deregulation in leukemia and lymphoma”, Immunity, 2012, vol. 36, pp. 529-541.
[cited by applicant]
CHMP, Guideline on Clinical Investigation of Medicinal Products indicated for the treatment of Psoriasis, 2004.
[cited by applicant]
Choy et al., “Cytokine pathways and joint inflammation in Rheumatoid Arthritis”, N. Engl. J. Med., 2001, vol. 344 (N 12): pp. 907-916.
[cited by applicant]
Chubinskaya et al., “Regulation of osteogenic proteins by chondrocytes”, Int. J. Biochem. & Cell Biology, 2003, vol. 35, pp. 1323-1340.
[cited by applicant]
Clegg et al., “Glucosamine, chondroitin sulfate and the two in combination for painful knee osteoarthritis”, N. Engl. J. Med., 2006, vol. 354(8), pp. 795-808.
[cited by applicant]
Communication pursuant to Art 94(3) EPC dated May 29, 2024, 5 pages.
[cited by applicant]
Constantinescu et al., “Mining for JAK-STAT mutations in cancer”, Trends in Biochemical Sciences, 2007, vol. 33(3), pp. 122-131.
[cited by applicant]
Dolgin et al., “Companies hope for kinase inhibitor JAKpot”, Nat Rev Drug Discovery, 2011, vol. 10, pp. 717-718.
[cited by applicant]
Drug Discovery and Development, Understanding the R&D process, Pharmaceutical Research and Manufacturers of America, 2007; pp. 1-14.
[cited by applicant]
Dymock, “Recent News in the Fast-Paced Field of JAK Inhibitors”, J Develop Drugs, 2013, vol. 2(2), pp. 1-2.
[cited by applicant]
Fabian et al., “A small molecule-kinase interaction map for clinical kinase ihibitors”,Nature Biotech, 2005, vol. 23(3), pp. 329-336.
[cited by applicant]
Firestein, G. S., “Evolving Concepts of Rheumatoid Arthritis”, Nature, 2003, vol. 423, No. 6937, pp. 356-361.
[cited by applicant]
First Examination Report received in AU Application No. 2019273664 dated May 14, 2024, 3 pages.
[cited by applicant]
Geron et al., “Selective inhibition of JAK2-driven erythroid diffferentiation of polycythemia”, Cancer Cell, 2008, vol. 13(4), pp. 321-330.
[cited by applicant]
Ingersoll et al., “The impact of medication regimen factors on adherence to chronic treatment: a review of literature”, J Behav Med, 2008, vol. 31(3), pp. 213-224.
[cited by applicant]
Ip et al., “Interleukin (IL)4 and IL-13 up-regulate monocyte chemoattractant protein-I”, British Society for Immunology: Clinical and Experimental Immunology, 2006, vol. 145, pp. 162-172.
[cited by applicant]
Jou et al., “Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis,” Arthritis & Rheum, 2005, vol. 1, pp. 339-344.
[cited by applicant]
Kachigian, “Collagen antibody-induced arthritis,” Nature Protocols, 2006, vol. 1, No. 5, pp. 2512-2516.
[cited by applicant]
Kopf et al., “Averting inflammation by targeting the cytokine environment”, Nat Rev Drug Discov, 2010, vol. 9, pp. 703-718.
[cited by applicant]
Kudlacz et al., “The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia,” Eur. J. Pharmaco, 2008, vol. 582, pp. 154-161.
[cited by applicant]
Labadie, et al., Design and evaluation novel 8-0×0-pyridopyrimidine JAK1/2, Bioorganic & Medicinal Chemistry Letters, 2013, vol. 23, pp. 5923-5930.
[cited by applicant]
Laurence, et al., “JAK Kinases in Health and Disease: An Update”, Open Rheumatology Journal, 2012, vol. 6 (2), pp. 232-244.
[cited by applicant]
Lee et al., “Rheumatoid arthritis”, Lancet, 2001, vol. 358, pp. 903-911.
[cited by applicant]
Legendre et al., “JAK/STAT but not ERK1/ERK2 pathway mediates interleuking . . . ”, J. Biol. Chem., 2003, vol. 278, No. 5, pp. 2903-2912.
[cited by applicant]
Levy et al., “STAT3 Signaling and the Hyper-IgE Syndrome,” N. Engl. J. Med., 2007, vol. 357, pp. 1655-1658.
[cited by applicant]
Li et al., “Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of . . . ”, J. of Immun., 2001, vol. 166, pp. 3491-3498.
[cited by applicant]
Lin et al., “Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents,” The British J. of Pharma., 2007, vol. 150, pp. 862-872.
[cited by applicant]
Lipinski et al., “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings”, Advanced Drug Delivery Reviews, 2001, vol. 46, pp. 3-26.
[cited by applicant]
McGinnity et al., “Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance,” Drug Metab Disp., 2004, vol. 32, No. 11, pp. 1247-1253.
[cited by applicant]
Milici et al., “Cartilage preservation by inhibition of Janus Kinase 3 in two rodent models of rheumatoid arthritis”, Arthritis Research & Therapy, 2008, vol. 10, pp. R14.
[cited by applicant]
Mullighan et al., “JAK mutations in high-risk childhood acute lymphoblastic leukemia”, Proc Natl Acad Sci, 2009, vol. 106(23), pp. 9414-9418.
[cited by applicant]
Naka et al., “The paradigm of IL-6: from basic science to medicine”, Arthritis Res, 2002, vol. 4, Suppl 3, pp. S233-S242.
[cited by applicant]
Nettekoven et al., “Synthetic Access to 2-Amido . . . ”, Synthesis, 2003, vol. 11, pp. 1649-1652.
[cited by applicant]
Nials et al., “Mouse Models of Allergic Asthma: Acute and Chronic Allergen Challenge,” Disease Models & Mechanisms, 2008, vol. 1, pp. 213-220.
[cited by applicant]
Nishida et al., “Histone Deacetylase Inhibitor Suppression ,” Arthritis & Rheum., 2004, vol. 50, pp. 3365-3376.
[cited by applicant]
O'Dell, “Therapeutic Strategies for Rheumatoid Arthritis”, N. Engl. J. Med, 2004, vol. 350, pp. 2591-2602.
[cited by applicant]
Office Action received in Chinese Application No. 201980034599 dated Jul. 21, 2023, with translation, 9 pages.
[cited by applicant]
Office Action received in Chinese Application No. 201980034599 dated May 8, 2024, with translation, 7 pages.
[cited by applicant]
Office Action received in Japanese Application No. 2020-565417 dated Apr. 25, 2023, with translation, 8 pages.
[cited by applicant]
Office Action received in Japanese Application No. 2020-565417 dated Oct. 17, 2023, with translation, 4 pages.
[cited by applicant]
Osaki et al., “The TAT A-containing core promoter of the type II collagen gene ,” Biochem J., 2003, vol. 369, pp. 103-115.
[cited by applicant]
Oshea et al., “A New Modality for Immunosuppresion: Targeting the JAK/STAT Pathway”, Nature Rev Drug Disc, vol. 3, 2004, pp. 555-554.
[cited by applicant]
O'Shea et al., “Cytokine Signaling Modules in Inflammatory Responses”, Immunity, 2008, vol. 28, pp. 477-487.
[cited by applicant]
O'Shea et al., “JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease”, Immunity, 2012, vol. 36, pp. 542-550.
[cited by applicant]
Oste et al., “A high throughput method of measuring bone architectural disturbance in a murine CIA model by micro-CT morphometry”, ECTC Montreal, 2007.
[cited by applicant]
O'Sullivan et al., “Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease”, Molecular Immunology, 2007, vol. 44(10), pp. 2497-2506.
[cited by applicant]
Otero et al., “Signaling pathway involved in nitric oxide synthase type II . . . ”, Arthritis Research & Therapy, vol. 7(3), pp. 581-591.
[cited by applicant]
Pernis et al., “JAK-STAT signaling in asthma”, J. Clin—Invest, 2002, vol. 109, pp. 1279-1283.
[cited by applicant]
Punwani et al., “Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis”, Journal of the American Academy of Dermatology, 2012, vol. 67(4), pp. 658-664.
[cited by applicant]
Rall et al., “Rheumatoid Cachexia: Metabolic Abnormalities, Mechanisms and Interventions”, Rheumatology, 2004, vol. 43, pp. 1219-1223.
[cited by applicant]
Rodig et al., “Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses”, Cell, vol. 93, 1998, pp. 373-383.
[cited by applicant]
Saharinen, et al., “Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain,” Molecular and Cellular Biology, vol. 20, No. 10, 2000, pp. 3387-3395.
[cited by applicant]
Salvemini, “Amelioration of Joint Disease in a Rat Model of Collagen-Induced Arthritis by M40403, a Superoxide Dismutase Mimetic”, Arthritis Rheum, vol. 44, No. 12, 2001, pp. 2909-2921.
[cited by applicant]
Seavey, et al., Biochemical Pharmacology, “The many faces of Janus kinase”, 2012, vol. 83, pp. 1136-1145.
[cited by applicant]
Shelton, Nerve Growth Factor Mediates Hyperalgesia and Cachexia in Auto-immune Arthritis, Pain, vol. 116, 2005, pp. 8-16.
[cited by applicant]
Sims, “Targeting Osteoclasts With Zoledronic Acid Prevents Bone Destruction in Collagen-Induced Arthritis” Arthritis Rheum., vol. 50, No. 7, 2004, pp. 2338-2346.
[cited by applicant]
Smolen JS, Steiner G., “Therapeutic Strategies for Rheumatoid Arthris”, Nat Rev Drug Discov., vol. 2, 2003, pp. 473-488.
[cited by applicant]
SoftFocus SFK Directed Libraries; Library SFK 39, “Serine-Threonine and Tyrosine Kinase directed,” BioFocus DPI, Advertising Article, 2006.
[cited by applicant]
Stahl et al., eds., “Handbook of pharmaceutical salts, Properties, selection and use”, Wiley-VCH, 2008, pp. 265-327.
[cited by applicant]
Tam et al., “Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer”, Br J Cancer, 2007, vol. 97(3), pp. 378-383.
[cited by applicant]
Vainchenker et al., “JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies”, Seminars in Cell & Developmental Biology, 2008, vol. 19(4), pp. 385-393.
[cited by applicant]
Verstovsek S., “Therapeutic Potential of JAK2 Inhibitors,” Hematology Am. Soc. Hematol. Educ. Program, 2009, pp. 636-642.
[cited by applicant]
Walsmith, “Tumor Necrosis Factor-a Production Is Associated with Less Body Cell Mass in Women with Rheumatoid Arthritis”, J Rheumatol., vol. 31, 2004, pp. 23-29.
[cited by applicant]
Wernig, “Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera”, Cancer Cell, vol. 13, No. 4, 2008, pp. 311-320.
[cited by applicant]
Wieland, et al., “Osteoarthritis—An Untreatable Disease?,” Nat Rev Drug Discov., vol. 4, No. 4, 2005, pp. 331-344.
[cited by applicant]
Wirtz, “Mouse Models of Inflammatory Bowel Disease”, Advanced Drug Delivery Reviews, vol. 59, 2007, pp. 1073-1083.
[cited by applicant]
Xiang, “Identification of Somatic JAK1 Mutations in Patients with Acute Myeloid Leukemia”, Blood, vol. 111, 2008, pp. 4809-4812.
[cited by applicant]
Yoshida, et al., Biochem & Biophysical Res Commun., “Low dose CP-690,550 (tofacitinib, a pan-JAK inhibitor . . . ,” 2012, vol. 418, pp. 234-240.
[cited by applicant]
Yu, et al., “Influence of Drug Release Properties of Conventional Solid Dosage Forms on the Systemic Exposure of Highly Soluble Drugs,” AAPS Pharmsci, vol. 3(3), 2001, pp. 86-92.
[cited by applicant]
Zenz, et al., “Psoriasis-like Skin Disease and Arthritis Caused by Inducible Epidermal Deletion of Jun Proteins,” Nature, vol. 437, 2005, pp. 369-375.
[cited by applicant]
Zhang, et al., “Activation of Jak/STAT Proteins Involved in Signal Transduction Pathway Mediated by Receptor for Interleukin 2 in Malignant T Lymphocytes Derived from Cutaneous Anaplastic Large T-cell Lymphoma and Sezar…
[cited by applicant]
Zikherman, et al., “Unraveling the Functional Implications of GWAS: How T Cell Protein Tyrosine Phosphatase Drives Autoimmune Disease”, J Clin Invest., 2011, vol. 121, No. 12, pp. 4618-4621.
[cited by applicant]